Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

The two companies worked together on blood cancer blockbuster Darzalex (daratumumab) – a CD38-targeting antibody which brought in almost $12 billion in sales worldwide last year – but J&J has ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Maladaptive immunity negatively impacts Alzheimer’s disease (AD). Here, the authors show dysfunctional CD38-expressing CD4 + T cells in individuals with familial AD before symptom onset.